In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Diagnostic accuracy of a novel ultra-sensitive cardiac troponin I assay compared to high-sensitivity cardiac troponin T and I for the early diagnosis of myocardial infarction

Session Poster Session 3

Speaker Raphael Twerenbold

Event : ESC Congress 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : R Twerenbold (Basel,CH), M Rubini Gimenez (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), C Puelacher (Basel,CH), P Badertscher (Basel,CH), J Du Fay De Lavallaz (Basel,CH), D Wussler (Basel,CH), N Kozhuharov (Basel,CH), O Miro (Barcelona,ES), FJ Martin-Sanchez (Madrid,ES), B Morawiec (Katowice,PL), D Keller (Zurich,CH), T Reichlin (Basel,CH), C Mueller (Basel,CH)

R. Twerenbold1 , M. Rubini Gimenez1 , J. Boeddinghaus1 , T. Nestelberger1 , C. Puelacher1 , P. Badertscher1 , J. Du Fay De Lavallaz1 , D. Wussler1 , N. Kozhuharov1 , O. Miro2 , F.J. Martin-Sanchez3 , B. Morawiec4 , D. Keller5 , T. Reichlin1 , C. Mueller1 , 1University Hospital Basel - Basel - Switzerland , 2Hospital Clinic de Barcelona - Barcelona - Spain , 3Hospital Clinic San Carlos - Madrid - Spain , 4Medical University of Silesia, Cardiology department - Katowice - Poland , 5University Hospital Zurich - Zurich - Switzerland ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 552

Background: Cardiac troponin plays a major role in the early diagnosis of myocardial infarction (MI). It remains unclear, whether the analytical superiority of a novel ultra-sensitive cardiac troponin I (us-cTnI) assay translates into clinical superiority when compared to high-sensitivity cardiac troponin (hs-cTn) T/I assays.

Purpose: We aimed to directly compare the diagnostic accuracy of a novel us-cTnI assay with a hs-cTnT and a hs-cTnI assay for the early diagnosis of MI.

Methods: In a prospective international multicentre diagnostic study enrolling patients presenting with suspected MI to the ED, us-cTnI-Clarity, hs-cTnT-Elecsys and hs-cTnI-Architect was determined at baseline and serially thereafter. Patients presenting with STEMI were excluded. Final diagnoses were centrally adjudicated by two independent cardiologists including all clinical information twice: first, using serial high-sensitivity (hs)-cTnT-Elecsys (primary analysis) and second, using hs-cTnI-Architect (secondary analysis) measurements in addition to the clinically used (hs)-cTnT/I. Primary objective was the direct comparison of the diagnostic accuracy, as quantified by the area under the receiver-operating-characteristic curve (AUC), of us-cTnI-Clarity with the two established hs-cTn assays (hs-cTnT-Elecsys, hs-cTnI-Architect).

Results: Among 2470 recruited patients, MI was the final diagnosis in 413 (17%). The diagnostic accuracy of measurements obtained at ED presentation, as quantified by AUCs, was 0.94 (95% CI, 0.93–0.95) for us-cTnI-Clarity and comparable to hs-cTnT-Elecsys (0.94; 95% CI, 0.93–0.95; p=0.367), and superior to hs-cTnI-Architect (0.93; 95% CI, 0.92–0.94; p=0.009; Figure 1A). Among patients presenting to the ED within 2h after chest pain onset (551/2470, 22%), the AUC was 0.92 (95% CI, 0.89–0.95) for us-cTnI-Clarity compared with 0.90 (95% CI, 0.86–0.93) for hs-cTnT-Elecsys and 0.90 (95% CI, 0.87–0.93) for hs-cTnI-Architect, respectively (p=0.118 and p=0.165 for respective direct comparisons; Figure 1B). Highly comparable findings were obtained when using the second final adjudicated diagnosis including hs-cTnI-Architect.

Conclusion: The diagnostic accuracy of the novel us-cTnI-Clarity assay for MI is very high and overall comparable to the two well-established hs-cTn assays.

Figure 1

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are